All terms in HP

Label Id Description
Chemosis HP_0012375 [Edema (swelling) of the bulbar conjunctiva.]
obsolete Abnormal globe morphology HP_0012374
Abnormal enzyme concentration or activity HP_0034684 [Concentration or activity of an enzyme is above or below the limits of normal.]
Fatigue HP_0012378 [A subjective feeling of tiredness characterized by a lack of energy and motivation.]
Abnormality of the eye HP_0000478 [Any abnormality of the eye, including location, spacing, and intraocular abnormalities.]
Hyperplasia of midface HP_0012371 [Abnormally anterior positioning of the infraorbital and perialar regions, or increased convexity of the face, or increased nasolabial angle. The midface includes the maxilla, the cheeks, the zygomas, and the infraorbital and perialar regions of the face]
Abnormal midface morphology HP_0000309 [An anomaly of the midface, which is a region and not an anatomical term. It extends, superiorly, from the inferior orbital margin to, inferiorly, the level of nasal base. It is formed by the maxilla (upper jaw) and zygoma and cheeks and malar region. Traditionally, the nose and premaxilla are not included in the midface.]
Prominence of the zygomatic bone HP_0012370 [Large or prominent malar surface of the zygomatic bone of the skull, which is convex and forms the prominence of the 'cheek bones'.]
Abnormal zygomatic bone morphology HP_0010668 [An abnormality of the zygomatic bone.]
ornithine CHEBI_18257 [An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.]
Acute bronchitis HP_0012388 [Inflammation of the large airways of the lung with rapid onset and short course usually associated with cough, mucus production, shortness of breath, wheezing, and chest tightness.]
Gly-Pro CHEBI_70744 [A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.]
dipeptide CHEBI_46761 [Any molecule that contains two amino-acid residues connected by peptide linkages.]
N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide CHEBI_18259 [A glycotetraosylceramide having N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucose as the tetrasaccharide component.]
globoside CHEBI_61360 [Any glycosphingolipid where the oligosaccharide component has an N-acetylgalactosaminyl residue at the non-reducing end.]
glycotetraosylceramide CHEBI_23075 [An oligoglycosylceramide consisting of a glycotetraosyl moiety attached to the ceramide oxygen with an unspecified N-acyl substituent attached to the ceramide nitrogen.]
N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide CHEBI_88167 [A glycotetraosylceramide having N-acetyl-beta-D-galactosaminyl-(1->3)-alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosyl component attached to the primary hydroxy function of a ceramide with undefined sphingoid base.]
Absent hallux HP_0012386 [Aplasia of the hallux, that is, a development defect such that the big toe does not develop.]
Aplasia/Hypoplasia of the hallux HP_0008362 [Absence or underdevelopment of the big toe.]
3,3',5-triiodo-L-thyronine CHEBI_18258 [An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.]